Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
43701	15/EE/0442	181302	Phase III Study of AG221 in Late Stage AML with IDH2 mutation	Number Agreed	2	2	Date Agreed	28/06/2019	0	03/07/2019	0	Recruitment Finished	Participants sought, 0 identified within time frame.
43702	17/EM/0063	213979	Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study	Number Agreed	2	2	Date Agreed	23/05/2019	4	23/05/2019	4	Recruitment Finished	
43703	17/LO/0236	220765	PROMINENT	Number Agreed	13	13	Date Agreed	31/05/2022	0	01/08/2019	0	Withdrawn By Sponsor	Sponsor closed recruitment early.
43704	17/EM/0060	215678	Protocol I1F-MC-RHBY	Number Agreed	1	1	Date Agreed	01/01/2019	1	01/01/2019	1	Recruitment Finished	
43705	17/WA/0111	225522	CR-AIR-009	Number Agreed	3	3	Date Agreed	01/12/2020	0	29/11/2019	0	Withdrawn By Sponsor	Sponsor closed recruitment early.
43706	17/EE/0074	217180	Lorlatinib (PF-06463922) Open Label Lung Cancer Study	Number Agreed	2	2	Date Agreed	31/10/2018	1	01/02/2019	1	Recruitment Finished	Participants sought, 1 identified within time frame.
43707	17/NI/0096	225743	HOPE-1	Number Agreed	2	2	Date Agreed	28/02/2019	2	22/05/2019	2	Recruitment Finished	
43708	17/YH/0369	232340	BGB-3111-304	Number Agreed	2	2	Date Agreed	30/04/2019	3	10/05/2019	3	Recruitment Finished	
43709	18/YH/0069	242258	GLOW study	Number Agreed	2	2	Date Agreed	03/03/2019	1	16/01/2019	1	Withdrawn By Sponsor	Sponsor closed recruitment early.
43710	18/NW/0507	250276	A Phase 1/2 Study of VX-121 in Subjects With Cystic Fibrosis and in Subjects without Cystic Fibrosis	Number Agreed	1	1	Date Agreed	13/02/2019	2	13/02/2019	2	Recruitment Finished	
43711	17/LO/1103	230709	Research doses of BAY1817080 in healthy males & PoC in chronic cough pts	Number Agreed	2	2	Date Agreed	31/01/2019	1	31/01/2019	1	Recruitment Finished	Participants sought, 1 identified within time frame.
43712	18/NW/0098	242717	Repeat doses of BAY 1902607 in healthy males and proof of concept in	Number Agreed	2	2	Date Agreed	03/06/2019	2	22/11/2019	2	Recruitment Finished	
43713	18/EM/0228	248988	Anti-viral effect of PC786 on RSV infection in HSCT recipients	Number Agreed	3	3	Date Agreed	31/08/2019	0	08/03/2019	0	Withdrawn By Sponsor	Sponsor closed recruitment early.
43714	18/YH/0477	253254	A Phase 3 study of Zanubrutinib compared with Ibrutinib	Number Agreed	3	3	Date Agreed	28/02/2020	3	24/10/2019	3	Withdrawn By Sponsor	Sponsor closed recruitment early.
43715	17/YH/0432	236091	GSK3772847 in participants with Asthma with AFAD	Number Agreed	3	3	Date Agreed	28/06/2019	1	20/06/2019	1	Withdrawn By Sponsor	Sponsor closed recruitment early.
43887	18/LO/0393	240955	A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy via Zinc Finger Nuclease (ZFN) mediated targeted integration of SB-FIX in Subjects with Severe Haemophilia B	Number Agreed	1	1	Date Agreed	31/12/2019	0	29/03/2019	0	Withdrawn By Sponsor	Study closed early by Sponsor due to insufficient benefit seen with the current first-generation ZFNs at the doses tested.
43888	18/YH/0398	251963	FreeStyle Libre Flash Glucose Monitoring System use in Insulin Treated Patients Undergoing Dialysis	Range Agreed	10	15	Date Agreed	19/02/2019	11	19/02/2019	11	Recruitment Finished	
43889	16/EM/0312	205489	A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered DS102 In Patients with NAFLD	Range Agreed	6	8	Date Agreed	30/06/2018	3	28/02/2019	3	Recruitment Finished	We Randomised 4 patients: it was difficult to recruit as the endpoint is ALT, the NASH patient do not have high enough ALT and it changes a lot without treatment. Recruitment depended on the ALT blood test. ALT levels change dramatically, especially without treatment, making prospective patients ineligible for the trial.
43890	17/LO/0848	222163	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis	Range Agreed	3	5	Date Agreed	30/04/2018	1	25/04/2019	1	Recruitment Finished	We screened 3 patients: 1 patient failed and wouldn't come back in to be re-tested and the other patient was unable to start treatment due to timelines. Due to a strict inclusion and 23 point exclusion criteria it was dificulty to recruit to this trial.
43891	17/EM/0406	235483	A Phase 1/2 Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia (PRTX-100-202)	Number Agreed	1	1	Date Agreed	31/03/2019	1	23/04/2019	1	Recruitment Finished	
43892	18/EM/0252	243309	Phase 3b Study for Management of Ocular Side Effects in Subjects with EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)	Number Agreed	4	4	Date Agreed	30/09/2019	2	15/05/2019	2	Withdrawn By Sponsor	Sponsor closed recruitment early

43893	18/EM/0147	238388	ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma	Number Agreed	2	2	Date Agreed	30/09/2019	0	01/04/2019	0	Withdrawn By Sponsor	Study opened March 2019 and was closed by the Sponsor in April 2019 as the treatment was found not to provide a clinical benefit to patients.
43894	15/SC/0682	186202	Efficacy and Safety of Lanreotide Autogel 120 Mg Administered Every 14 Days in Well Differentiated, Metastatic Or Locally Advanced, Unresectable Pancreatic Or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lan	Number Agreed	4	4	Date Agreed	31/07/2018	6	31/01/2019	6	Recruitment Finished	
43895	15/NE/0143	174391	A Phase Iii, Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate the Efficacy and Safety of Etrolizumab As An Induction and Maintenance Treatment for Patients With Moderately To Severely Active Crohn's Disease	Number Agreed	3	3	Date Agreed	31/12/2018	1	31/01/2019	1	Recruitment Finished	There were other competing studies which took priority. We made the decision to close recruitment at our site.
43896	17/LO/0889	211287	Phase II/III randomized, double-blind study of Sandostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced G1-G2 neuroendocrine tumors of non-pancreatic origin	Number Agreed	7	7	Date Agreed	01/05/2019	0	08/05/2019	0	Recruitment Finished	The clinical environment changed with other more effective therapies becoming available on the NHS.
43897	17/LO/0041	219676	CardioMEMS HF System Post Market Study	Range Agreed	5	10	Date Agreed	30/09/2019	7	31/07/2019	7	Withdrawn By Sponsor	Sponsor closed recruitment early
43898	18/SC/0009	238195	An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)	Number Agreed	4	4	Date Agreed	27/08/2020	4	07/06/2019	4	Withdrawn By Sponsor	Sponsor closed recruitment early
43899	16/WM/0365	210358	A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative c	Number Agreed	2	2	Date Agreed	19/12/2018	0	31/01/2019	0	Recruitment Finished	We Screened 34 Patients but all failed the 26 point exclusion criteria.
43900	18/SC/0022	237771	A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986224 in Healthy Subjects and Chronic Heart Failure Patients with Reduced Eject	Range Agreed	2	3	Date Agreed	29/04/2019	0	08/03/2019	0	Withdrawn By Sponsor	We screened 21 patients in total, however patients were either not eligible or refused to take part in the study. The study was halted by the sponsor due to a serious breach in March .
43901	18/EM/0086	236856	A 2-year prospective study to evaluate the onset of action of Mavenclad ® in subjects with highly active relapsing multiple sclerosis	Range Agreed	3	5	Date Agreed	31/12/2019	2	29/08/2019	2	Withdrawn By Sponsor	Sponsor closed recruitment early
43902	17/LO/1350	231231	A Phase 3, Open Label, Switch Over Study to Assess the Safety, Efficacy and Pharmacokinetics of pegunigalsidase alfa (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks for 52 weeks in Patients with Fabry Disease Currently Treated with En	Number Agreed	5	5	Date Agreed	30/09/2018	0	30/04/2019	0	Recruitment Finished	Patients prefered to continue with home infusions and were not keen to attend hospital for study visits
43903	18/YH/0063	234608	A Prospective, Multi-Center Evaluation of the ENSEAL X1 Large Jaw Tissue Sealer	Number Agreed	8	8	Date Agreed	31/07/2019	9	31/07/2019	9	Recruitment Finished	
43904	18/SC/0241	244567	A phase 2a proof of concept, randomised, double-blind, placebo-controlled study to evaluate the safety/tolerability and efficacy of 4 subcutaneous injections of namilumab (150 mg) given over 10 weeks in subjects with moderate-to-severely active axial spondyloarthritis including those previously exposed to anti-TNF therapy (NAMASTE study)	Number Agreed	4	4	Date Agreed	14/06/2019	5	14/06/2019	5	Recruitment Finished	
43905	17/LO/0243	219613	A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary biliary cholangitis	Number Agreed	2	2	Date Agreed	18/02/2019	4	10/10/2019	5	Recruitment Finished	
43906	18/YH/0012	237184	A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids (TCS) in subjects with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.	Range Agreed	2	6	Date Agreed	31/08/2018	3	15/05/2019	4	Recruitment Finished	
43907	18/LO/0727	245123	Post-Market Clinical Follow-Up Study to Monitor Device Performance and Outcomes of the CENTERA Transcatheter Heart Valve System	Number Agreed	10	10	Date Agreed	30/09/2019	8	31/08/2019	8	Withdrawn By Sponsor	Recruitment closed early by sponsor due to Termination of the CENTERA THV program.

43908	18/WM/0372	250761	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Weakness	Number Agreed	1	1	Date Agreed	31/12/2019	0	24/09/2019	0	Withdrawn By Sponsor	Sponsor closed recruitment early.
43909	18/SS/0129	251855	A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy	Number Agreed	3	3	Date Agreed	31/08/2020	0	15/10/2019	0	Withdrawn By Sponsor	Sponsor closed all UK sites 10 months before end of recruitment.
43910	17/SC/0237	220963	A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and pharmacokinetics of different doses of orally administered BI 1467335 during a 12-week treatment period compared to placebo in patients with clinical evidence of NASH.	Number Agreed	5	5	Date Agreed	17/01/2018	0	01/02/2019	0	Recruitment Finished	Trial protocol, ALT result. Low recruitment across the whole of the UK. Poor uptake as phase 2 study dose finding. Frequency of study visits and long PK 8 hour days for patients is off-putting. Change in site staff and closure of the study on temporary hold due to a safety issue.
43911	17/NE/0149	224550	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer	Number Agreed	6	6	Date Agreed	31/12/2020	2	12/07/2019	2	Withdrawn By Sponsor	Sponsor closed recruitment early
43912	17/LO/2060	230779	A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)	Range Agreed	1	2	Date Agreed	30/09/2019	4	23/09/2019	4	Withdrawn By Sponsor	Sponsor closed recruitment early
43913	16/LO/1466	210027	A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidase Beta	Number Agreed	2	2	Date Agreed	01/05/2019	1	30/09/2019	1	Recruitment Finished	The strict eligibility criteria impacted on our recruitment.
43914	18/NE/0142	242919	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis Protocol 747-304	Range Agreed	3	5	Date Agreed	31/10/2019	3	22/11/2019	4	Recruitment Finished	
43915	18/WA/0211	240366	A PHASE 2 DOSE RANGING, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF EDP-305 IN SUBJECTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) WITH OR WITHOUT AN INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID (UDCA)	Range Agreed	2	3	Date Agreed	30/09/2019	2	27/09/2019	2	Withdrawn By Sponsor	Sponsor closed recruitment early
43916	18/NW/0215	239446	A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis	Range Agreed	1	2	Date Agreed	30/06/2020	1	09/07/2019	1	Withdrawn By Sponsor	Sponsor closed recruitment early
43917	15/YH/0478	186697	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Range Agreed	5	10	Date Agreed	30/06/2018	6	17/06/2019	6	Recruitment Finished	